Cure SMA Clinical Care Session 2021: Enduring Activity

TARGET AUDIENCE

This activity is intended for health care providers who diagnose and care for people affected by SMA, including physicians, nurse practitioners, physician assistants and nurses, pediatric and adult specialists including neurologists, pulmonologists, rehabilitation medicine, genetics, orthopedic surgery, palliative care, physical and occupational therapists, speech and language pathologists, pharmacists, nutritionists, genetic counselors, social workers, respiratory therapists, and trainees in the above disciplines.

ACTIVITY OBJECTIVES

The learning objectives for this activity are:

  • Demonstrate knowledge of multidisciplinary team roles and responsibilities in care management to optimize SMA outcomes
  • Describe the existing and evolving treatment options for patients with SMA
  • Describe the impact of new treatments on the SMA phenotype
  • Analyze the treatment options for management of infants with SMA identified by SMA newborn screening
  • Demonstrate knowledge risk for mental health complications of SMA
  • Describe the application of mental health screening tools for SMA outpatient use

ELEMENTS OF COMPETENCE

This activity has been designed to change learner competence and focuses on the American Board of Medical Specialties areas of patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice. This activity also focuses on the interprofessional competencies of values/ethics for interprofessional practice, interprofessional communication, and teams/teamwork.

Course summary
Available credit: 
  • 5.50 AAPA Category 1 CME
  • 5.50 MOC: ABIM Medical Knowledge Points (Part II)
  • 5.50 MOC: ABP Lifelong Learning Points (Part II)
  • 5.50 ACPE Contact Hours - Pharmacist
  • 5.50 AMA PRA Category 1 Credit
  • 5.50 ANCC Contact Hours
  • 5.50 APA CE Credits
  • 5.00 Physical Therapy Contact Hours
  • 5.50 ACE Credits
  • 5.50 University of Wisconsin–Madison Continuing Education Hours
    • 5.50 Approved for AMA PRA Category 1 Credit™
Registration opens: 
11/01/2021
Course expires: 
10/31/2022
Cost:
$0.00
Rating: 
0

PRESENTATIONS AND SPEAKERS

Welcome and CMO Update, Mary Schroth, MD
Cure SMA Community Database Outcomes, Lisa Belter, MPH
Special Session: Ethics, Moderator: Julie Parsons, MD; Panelists: Thomas Crawford, MD, John Brandsema, MD, Bakri Elsheikh, MD; Ethicist: Brian Jackson, MD, MA
Single Institution Experience of Nusinersen Treatment of Adult Patients with Spinal Muscular Atrophy, Meghan Moore, PT, DPT, NCS
Clinical Efficacy and Safety of Risdiplam Use as Combination Therapy in Spinal Muscular Atrophy (SMA) Patients Post Onasemnogene-Abeparvovec-Xioi (Onasemnogene) and/or Nusinersen Use, Kapil Arya, MBBS, FAAP, FANA, Paul Drake, MD
Nusinersen by Subcutaneous Catheter for Spinal Muscular Atrophy, Karlla Brigatti, MS, CGC
MUSCULOSKELETAL PANEL
A. Bracing for Scoliosis in Spinal Muscular Atrophy: Is It Effective, Brian Snyder, MD, PhD
B. 20 Year Experience with Segmental Sublaminar Instrumentation for Guided Growth in Early Onset Scoliosis, Samuel R. Rosenfeld, MD
C. Hip Pain Assessment in Patients with Spinal Muscular Atrophy: Prevalence, Intensity, Interference, and Associated Factors, Amy Xu, BS
D. Development of a Competency-Based Educational Program for Spinal Muscular Atrophy Physical Therapists (STEP-IN), Jacqueline Montes, PT, EdD
Special Session: Mental Health Screening and Management Tools, Moderator: Vamshi Rao, MD; Speakers and Panelists: Pamela Mosher, MD, Vanessa Battista, RN, MS, CPNP-PC, CHPPN, Diane Murrell, LCSW, Al Freedman, PhD
SMA NEWBORN SCREENING PANEL
A. Integrating a Pilot Newborn Screening for Spinal Muscular Atrophy into the Australian Public Healthcare System, Arlene D'Silva, PhD
B. Statewide Newborn Screening for Spinal Muscular Atrophy: The Wisconsin Experience, Mei Baker, MD
C. The Clinicians and Families Experience with the First Year of Newborn Screening in Colorado and Wyoming, Melissa Gibbons, MS, CGC
D. Investigating the SMA Patient Community's Attitudes Towards Fetal Therapy, Marisa Schwab, MD


 

 

 

FACULTY

Kapil Arya, MBBS, FAAP, FANA, Associate Professor of Pediatric Neurology, University of Arkansas College of Medicine

Mei Baker, MD, Professor, Pediatrics-Genetics and Metabolism, University of Wisconsin School of Medicine and Public Health

Vanessa Battista, RN, MS, CPNP-PC, CHPPN, NP, Division of Neurology, Children's Hospital of Philadelphia

Lisa Belter, MPH, Cure SMA

John Brandsema, MD, Assistant Professor of Clinical Neurology, Children's Hospital of Philadelphia

Karlla Brigatti, MS, CGC, Research Operations Director, Clinic for Special Children, Pennsylvania

Thomas Crawford, MD, Professor of Neurology, Johns Hopkins School of Medicine

Arlene D'Silva, PhD, Post-Doctoral Researcher, Western Sydney University

Paul Drake, MD, Child Neurology Resident, University of Arkansas College of Medicine

Bakri Elsheikh, MD, Associate Professor of Clinical Neurology, The Ohio State University Wexner Medical Center

Al Freedman, PhD, Licensed Psychologist, Freedman Counseling Associates

Melissa Gibbons, MS, CGC, Assistant Professor, Pediatrics-Clinical Genetics and Metabolism, University of Colorado School of Medicine

Brian Jackson, MD, MA, Assistant Professor of Pediatric Critical Care Medicine; Chair of Ethics Committee, Children's Hospital of Colorado

Jacqueline Montes, PT, EdD, Assistant Professor of Clinical Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center

Meghan Moore, PT, DPT, NCS, Board-Certified Neurological Clinical Specialist, Johns Hopkins Children's Center

Pamela Mosher, MD, Assistant Professor, Department of Psychiatry, University of Toronto

Diane Murrell, LCSW, Texas Children's Hospital

Julie Parsons, MD, Professor of Clinical Pediatrics and Neurology, Children's Hospital of Colorado

Vamshi Rao, MD, Assistant Professor of Pediatrics (Neurology and Epilepsy), Children's Hospital of Chicago

Samuel Rosenfeld, MD, Clinical Associate Professor, Department of Orthopedic Surgery, Children's Health Orange County, University of California Irvine

Mary Schroth, MD, Chief Medical Officer, Cure SMA

Marisa Schwab, MD, General Surgery Resident, University of California San Francisco Medical Center

Brian Snyder, MD, PhD, Professor of Orthopedic Surgery, Boston Children's Hospital

Amy Xu, BS, Medical Student, Johns Hopkins School of Medicine

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters, and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by, or on, patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.

             

NAME

 

ROLE(S)

 

FINANCIAL RELATIONSHIPS DISCLOSURE

DISCUSSION OF UNLABELED/

UNAPPROVED USES OF DRUGS/DEVICES

IN PRESENTATION?

Kapil Arya, MBBS

Presenter

No relevant relationships with ineligible companies to disclose

No

Mei Baker, MD

Presenter

No relevant relationships with ineligible companies to disclose

No

Vanessa Battista, RN, MS

Planner,

Presenter

AveXis; Biogen; Novartis; PTC Therapeutics, Inc. (All Contractor)

No

William Bell, PharmD, MBA

Planner

No relevant relationships with ineligible companies to disclose

N/A

Lisa Belter, MPH

Presenter

No relevant relationships with ineligible companies to disclose

No

John Brandsema, MD

Planner, Presenter

Alexion Pharmaceuticals; Biogen; Catabasis; CSL Behring; FibroGen; Novartis; PTC Therapeutics, Inc.; Pfizer; Sarepta Therapeutics, Inc.; Summit, WaVe (All Grant); Audentes; Biogen Idec; Cytokinetics; Genentech; Momenta Pharmaceuticals, Inc.; Novartis Pharma; NS Pharma; PTC Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock; WaVe (All Contractor)

No

Karlla Brigatti, MS, CGC

Presenter

Biogen, Inc.; Novartis (Grant); Novartis (Contractor)

No

Jin Yun Chen, MS, CGC

Planner

No relevant relationships with ineligible companies to disclose

N/A

Thomas Crawford, MD

Planner, Presenter

Biogen, Inc.; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor)

No

Arlene D’Silva, PhD

Presenter

No relevant relationships with ineligible companies to disclose

No

Paul Drake, MD

Presenter

No relevant relationships with ineligible companies to disclose

No

Bakri Elsheikh, MD

Planner, Presenter

Biogen (Contractor and Grant); Genentech (Contractor)

No

Albert Freedman, PhD

Planner, Presenter

Genentech; Novartis (Both Contractor)

No

Melissa Gibbons, MS, CGS

Planner, Presenter

Biogen; Novartis (Both Grant)

No

Jennifer Hubbell, BS

Presenter

No relevant relationships with ineligible companies to disclose

No

Becky Hurst-Davis, MS, RD

Planner

No relevant relationships with ineligible companies to disclose

N/A

Brian Jackson, MD, MA

Presenter

No relevant relationships with ineligible companies to disclose

No

Chamindra Konersman, MD

Planner

Biogen, Inc.; Novartis Pharma; Sarepta Therapeutics, Inc. (All Contractor)

N/A

Richard Kravitz, MD

Planner

AveXis; Biogen, Inc.; Santhera (All Contractor)

N/A

Kristin Krosschell, PT, DPT

Planner

ASPA Therapeutics; Biogen; Genentech; Novartis; (All Contractor); Biogen (Grant)

N/A

Oren Kupfer, MD

Planner

No relevant relationships with ineligible companies to disclose

N/A

Cathy Means, MS

Planner

No relevant relationships with ineligible companies to disclose

N/A

Jacqueline Montes, PT, EdD

Presenter

Biogen, Inc.; F. Hoffmann-LaRoche; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor)

No

Meghan Moore, PT, DPT

Presenter

Biogen, Inc.; Genentech (Both Contractor)

No

Pamela Mosher, MD

Presenter

No relevant relationships with ineligible companies to disclose

No

Diane Murrell, LCSW

Planner, Presenter

No relevant relationships with ineligible companies to disclose

No

Leslie Nelson

Planner

Avexis; Biogen, Inc.; F. Hoffmann-La Roche; Genentech; Novartis; Scholar Rock (All Contractor)

N/A

Julie Parsons, MD

Planner, Moderator

Biogen; Genentech; Novartis; Scholar Rock (All Contractor)

No

Vamshi Rao, MD

Moderator

Avexis; Biogen; Capricor; Genentech; NSpharma; PTC Therapeutics, Inc.; RegenxBio; Sarepta Therapeutics, Inc.; Scholar Rock; Watermark (All Contractor)

No

Samuel Rosenfeld, MD

Planner, Presenter

OrthoPediatrics Corp. (Contractor)

No

Peter Schochet, MD

Planner

No relevant relationships with ineligible companies to disclose

N/A

Mary Schroth, MD

Planner, Medical Director

Audentes Therapeutics (Contractor)

No

Marisa Schwab, MD

Presenter

No relevant relationships with ineligible companies to disclose

No

Edward Smith, MD

Planner

Biogen; Genentech; Novartis (All Contractor)

N/A

Brian Snyder, MD, PhD

Presenter

Alcyone; OrthoPediatrics Corp. (Both Contractor)

No

Anne Stratton, MD

Planner

No relevant relationships with ineligible companies to disclose

N/A

Stacey Tarrant, RD, LDN

Planner

No relevant relationships with ineligible companies to disclose

N/A

Laura Watne, MD, RD

Planner

No relevant relationships with ineligible companies to disclose

N/A

Elanda Williams, MA

Planner

No relevant relationships with ineligible companies to disclose

N/A

Amy Xu, BS

Presenter

No relevant relationships with ineligible companies to disclose

No

 

Discloser List CME Internal Report

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

 

 

American Medical Association (AMA)

The University of Wisconsin-Madison ICEP designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pediatrics

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

American Academy of Physician Assistants (AAPA)

The University of Wisconsin-Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. Approval is valid until November 1, 2022. PAs should only claim credit commensurate with the extent of their participation.

 

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this enduring material for a maximum of 5.5 ANCC contact hours.

 

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this enduring material for 5.5 hours/0.55 CEUs of CPE credit. Credit can be earned successfully completing the activity, the assessment, and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

University Activity Number (UAN) UAN JA0000358-9999-21-155-04-P. 5.5 hours/0.55 CEUs

American Psychological Association (APA)

(CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

 

ASWB Approved Continuing Education (ACE) Social Work Credit

As a Jointly Accredited Organization, the University of Wisconsin–Madison ICEP is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The University of Wisconsin–Madison ICEP maintains responsibility for this course. Social workers completing this course receive 5.5 enduring continuing education credits.

 

Wisconsin Physical Therapy Association (WPTA)

This activity has been approved by the APTA Wisconsin for 5.50 credits (Approval Number 18328).

 

Continuing Education Units (CEUs)

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for .55 CEUs or 5.5 hours.

 

 

 

 

 

Available Credit

  • 5.50 AAPA Category 1 CME
  • 5.50 MOC: ABIM Medical Knowledge Points (Part II)
  • 5.50 MOC: ABP Lifelong Learning Points (Part II)
  • 5.50 ACPE Contact Hours - Pharmacist
  • 5.50 AMA PRA Category 1 Credit
  • 5.50 ANCC Contact Hours
  • 5.50 APA CE Credits
  • 5.00 Physical Therapy Contact Hours
  • 5.50 ACE Credits
  • 5.50 University of Wisconsin–Madison Continuing Education Hours
    • 5.50 Approved for AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Computer, tablet, or smartphone with audio sharing capabilities.